With opiod addiction skyrocketing in the United States and especially in our rural communities, the latest data indicates that drug overdose deaths in the US increased by approximately 21 percent between 2015 and 2016. This was an increase from a record high of more than 52,000 to a new record of nearly 64,000. Unfortunately, approximately two-thirds of those overdoses were linked to opioids.
With American consuming more opiods than any other country, the questions we must ask is "Why?" Perhaps it is because life has lost meaning for many of the American population due to economic and social changes. Maybe this meaninglessness is further contributing to total despair? Help and further treatment is on the horizon. A new opioid addiction treatment that is injected monthly instead of taken daily as a tablet was approved recently by the Food and Drug Administration. This new product is known as Sublocade.
It is speculated that this new version of the drug may help patients reduce relapses, disrupt the treatment market, and possibly dispel misconceptions about the drug’s potential for abuse. It has been reiterated across various professional organizations that this treatment could become the first-line medication for opioid addiction replacing naloxone. Further, It could open up opportunities for getting more patients on buprenorphine.
The new product, known as Sublocade
Tracy A. Jones is an American Heart Association Master Program Trainer, Instructor, & AHA Faculty Member located in San Antonio, Texas.